{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/RAA/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"RAA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RAA\",,,,,undefined,":{"symbol":"RAA","market":"US","secType":"STK","nameCN":"SMI 3Fourteen REAL Asset Allocation ETF","latestPrice":24.1187,"timestamp":1745870400000,"preClose":24.0551,"halted":0,"volume":33827,"delay":0,"floatShares":15900000,"shares":0,"eps":0,"marketStatus":"Not Yet Opened","change":0.0636,"latestTime":"04-28 16:00:00 EDT","open":24.14,"high":24.14,"low":23.9248,"amount":812554.6626,"amplitude":0.008946,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745913600000},"marketStatusCode":0,"adr":0,"exchange":"NASDAQ","adjPreClose":24.0551,"sharesOutstanding":15900000,"nav":24.04,"aum":382236000,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":24.23,"preClose":24.0551,"latestTime":"09:29 EDT","volume":201,"amount":4915.3599269999995,"timestamp":1745846966001},"volumeRatio":0.920843},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RAA\",,,,,undefined,":{"symbol":"RAA","floatShares":15900000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.920843,"shares":0,"dividePrice":0,"high":24.14,"amplitude":0.008946,"preClose":24.0551,"low":23.9248,"week52Low":21.935,"pbRate":"--","week52High":26.57,"institutionHeld":0,"latestPrice":24.1187,"eps":0,"divideRate":0,"volume":33827,"delay":0,"ttmEps":0,"open":24.14,"prevYearClose":25.1,"prevWeekClose":24.0551,"prevMonthClose":24.1,"prevQuarterClose":24.1,"fiveDayClose":22.9404,"twentyDayClose":24.0329},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RAA\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2518224329","title":"MannKind Showcases Efficacy, Safety, and Mealtime Control Data from Recent Pediatric and Adult Studies of Afrezza® at the ATTD Conference, March 19-22","url":"https://stock-news.laohu8.com/highlight/detail?id=2518224329","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518224329?lang=en_us&edition=fundamental","pubTime":"2025-03-10 18:05","pubTimestamp":1741601100,"startTime":"0","endTime":"0","summary":"Five presentations affirm positive outcomes utilizing inhaled insulinAn sNDA filing for Afrezza in pediatric population anticipated in 2025 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., March  10, 2025   -- MannKind Corporation , a company focused on the development and commercialization of inhaled therapeutic products and delivery devices for patients with endocrine and orphan lung diseases, will showcase data from recent studies of inhaled insulin across five presentations at the 18th International Conference on Advanced Technologies and Treatments for Diabetes to be held March 19-22 in Amsterdam. “Data from both the INHALE-1 pediatric and INHALE-3 adult studies continue to drive groundbreaking conversations around inhaled insulin,” said Dr. Kevin Kaiserman, Senior Vice President, Therapeutic Area Head, Endocrine Diseases for MannKind Corporation. \"Afrezza continues to be an important treatment option for adults living with diabetes, including those utilizing MDI and AID, and we look ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/10/3039535/29517/en/MannKind-Showcases-Efficacy-Safety-and-Mealtime-Control-Data-from-Recent-Pediatric-and-Adult-Studies-of-Afrezza-at-the-ATTD-Conference-March-19-22.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4584","RAA","RCT","CET","BK4139","MNKD"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":1,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RAA\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RAA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"RAA\",market:\"US\",delay:false,,,undefined,":{}}}